EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Protective effect of pre-existing natural immunity in a nonhuman primate reinfection model of congenital cytomegalovirus infection

Matilda J Moström iD, Shan Yu, Dollnovan Tran, Frances M Saccoccio, Cyril J Versoza, Daniel Malouli, Anne Mirza, Sarah Valencia, Margaret Gilbert, Robert V Blair, Scott Hansen, Peter Barry und 6 weitere

PLOS Pathogens · 2023

DOI: 10.1371/journal.ppat.1011646 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Matilda J Moström und 17 weiteren Autor:innen. Beteiligte Einrichtung: Tulane National Primate Research Center, Tulane University, Covington, Louisiana, United States of America. Hauptthemen laut MEDLINE: Cytomegalovirus, Cytomegalovirus Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Congenital cytomegalovirus (cCMV) is the leading infectious cause of neurologic defects in newborns with particularly severe sequelae in the setting of primary CMV infection in the first trimester of pregnancy. The majority of cCMV cases worldwide occur after non-primary infection in CMV-seropositive women; yet the extent to which pre-existing natural CMV-specific immunity protects against CMV reinfection or reactivation during pregnancy remains ill-defined. We previously reported on a novel nonhuman primate model of cCMV in rhesus macaques where 100% placental transmission and 83% fetal loss were seen in CD4 + T lymphocyte-depleted rhesus CMV (RhCMV)-seronegative dams after primary RhCMV infection. To investigate the protective effect of preconception maternal immunity, we performed reinfection studies in CD4+ T lymphocyte-depleted RhCMV-seropositive dams inoculated in late first / early second trimester gestation with RhCMV strains 180.92 ( n = 2), or RhCMV UCD52 and FL-RhCMVΔRh13.1/SIV gag , a wild-type-like RhCMV clone with SIV gag inserted as an immunological marker, administered separately ( n = 3). An early transient increase in circulating monocytes followed by boosting of the pre-existing RhCMV-specific CD8+ T lymphocyte and antibody response was observed in the reinfected dams but not in control CD4+ T lymphocyte-depleted dams. Emergence of SIV Gag-specific CD8+ T lymphocyte responses in macaques inoculated with the FL-RhCMVΔRh13.1/SIV gag virus confirmed reinfection. Placental transmission was detected in only one of five reinfected dams and there were no adverse fetal sequelae. Viral whole genome, short-read, deep sequencing analysis confirmed transmission of both reinfection RhCMV strains across the placenta with ~30% corresponding to FL-RhCMVΔRh13.1/SIV gag and ~70% to RhCMV UCD52, consistent with the mixed human CMV infections reported in infants with cCMV. Our data showing reduced placental transmission and absence of fetal loss after non-primary as opposed to primary infection in CD4+ T lymphocyte-depleted dams indicates that preconception maternal CMV-specific CD8+ T lymphocyte and/or humoral immunity can protect against cCMV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytomegalovirusCytomegalovirus InfectionsInfant, NewbornAnimalsFemalePregnancyHumansMacaca mulattaReinfectionPlacentaImmunity, Innate

Autor:innen und Institutionen

  • Tulane National Primate Research Center, Tulane University, Covington, Louisiana, United States of America.
  • Duke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
  • Center for Evolution & Medicine, School of Life Sciences, Arizona State University, Tempe, Arizona, United States of America.
  • Oregon Health and Sciences University, Beaverton, Oregon, United States of America.
  • University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.
  • University of California, Davis, California, United States of America.

ORCID-Profile: Matilda J Moström, Amitinder Kaur

Förderung

  • NICHD NIH HHS
  • NIH HHS
  • NIAID NIH HHS
  • NIH

Zitieren

APA

Moström, M. J., Yu, S., Tran, D., Saccoccio, F. M., Versoza, C. J., Malouli, D., Mirza, A., Valencia, S., Gilbert, M., Blair, R. V., Hansen, S., Barry, P., Früh, K., Jensen, J. D., Pfeifer, S. P., Kowalik, T. F., Permar, S. R., & Kaur, A. (2023). Protective effect of pre-existing natural immunity in a nonhuman primate reinfection model of congenital cytomegalovirus infection. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011646

Vancouver

Moström MJ, Yu S, Tran D, Saccoccio FM, Versoza CJ, Malouli D, et al. Protective effect of pre-existing natural immunity in a nonhuman primate reinfection model of congenital cytomegalovirus infection. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011646

BibTeX
@article{Mostrm2023,
  author = {Moström, Matilda J and Yu, Shan and Tran, Dollnovan and Saccoccio, Frances M and Versoza, Cyril J and Malouli, Daniel and Mirza, Anne and Valencia, Sarah and Gilbert, Margaret and Blair, Robert V and Hansen, Scott and Barry, Peter and Früh, Klaus and Jensen, Jeffrey D and Pfeifer, Susanne P and Kowalik, Timothy F and Permar, Sallie R and Kaur, Amitinder},
  title = {Protective effect of pre-existing natural immunity in a nonhuman primate reinfection model of congenital cytomegalovirus infection},
  journal = {PLOS Pathogens},
  year = {2023},
  doi = {10.1371/journal.ppat.1011646}
}
Kostenlos starten →